Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
Identifieur interne : 000451 ( PubMed/Corpus ); précédent : 000450; suivant : 000452Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
Auteurs : H S Han ; V. Diéras ; M. Robson ; M. Palácová ; P K Marcom ; A. Jager ; I. Bondarenko ; D. Citrin ; M. Campone ; M L Telli ; S M Domchek ; M. Friedlander ; B. Kaufman ; J E Garber ; Y. Shparyk ; E. Chmielowska ; E H Jakobsen ; V. Kaklamani ; W. Gradishar ; C K Ratajczak ; C. Nickner ; Q. Qin ; J. Qian ; S P Shepherd ; S J Isakoff ; S. PuhallaSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.
DOI: 10.1093/annonc/mdx505
PubMed: 29045554
Links to Exploration step
pubmed:29045554Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.</title><author><name sortKey="Han, H S" sort="Han, H S" uniqKey="Han H" first="H S" last="Han">H S Han</name><affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, FL.</nlm:affiliation></affiliation></author><author><name sortKey="Dieras, V" sort="Dieras, V" uniqKey="Dieras V" first="V" last="Diéras">V. Diéras</name><affiliation><nlm:affiliation>Institut Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Robson, M" sort="Robson, M" uniqKey="Robson M" first="M" last="Robson">M. Robson</name><affiliation><nlm:affiliation>Weill Cornell Medical College, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Palacova, M" sort="Palacova, M" uniqKey="Palacova M" first="M" last="Palácová">M. Palácová</name><affiliation><nlm:affiliation>Masarykuv onkologický ústav, Brno, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Marcom, P K" sort="Marcom, P K" uniqKey="Marcom P" first="P K" last="Marcom">P K Marcom</name><affiliation><nlm:affiliation>Duke University; Durham, NC.</nlm:affiliation></affiliation></author><author><name sortKey="Jager, A" sort="Jager, A" uniqKey="Jager A" first="A" last="Jager">A. Jager</name><affiliation><nlm:affiliation>Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Bondarenko, I" sort="Bondarenko, I" uniqKey="Bondarenko I" first="I" last="Bondarenko">I. Bondarenko</name><affiliation><nlm:affiliation>Dnepropetrovsk Medical Academy, City Hospital #4, Dnipro, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Citrin, D" sort="Citrin, D" uniqKey="Citrin D" first="D" last="Citrin">D. Citrin</name><affiliation><nlm:affiliation>Midwestern Regional Medical Center, Zion, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M" last="Campone">M. Campone</name><affiliation><nlm:affiliation>Institut de Cancérologie de l'Ouest, Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="Telli, M L" sort="Telli, M L" uniqKey="Telli M" first="M L" last="Telli">M L Telli</name><affiliation><nlm:affiliation>Stanford University School of Medicine, Stanford, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Domchek, S M" sort="Domchek, S M" uniqKey="Domchek S" first="S M" last="Domchek">S M Domchek</name><affiliation><nlm:affiliation>University of Pennsylvania, Philadelphia, PA.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M" last="Friedlander">M. Friedlander</name><affiliation><nlm:affiliation>Prince of Wales Hospital, Sydney, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufman, B" sort="Kaufman, B" uniqKey="Kaufman B" first="B" last="Kaufman">B. Kaufman</name><affiliation><nlm:affiliation>Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Garber, J E" sort="Garber, J E" uniqKey="Garber J" first="J E" last="Garber">J E Garber</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Shparyk, Y" sort="Shparyk, Y" uniqKey="Shparyk Y" first="Y" last="Shparyk">Y. Shparyk</name><affiliation><nlm:affiliation>Chemotherapy Department, Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Chmielowska, E" sort="Chmielowska, E" uniqKey="Chmielowska E" first="E" last="Chmielowska">E. Chmielowska</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Oncology Centre, Bydgoszcz, UMK, Torun, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Jakobsen, E H" sort="Jakobsen, E H" uniqKey="Jakobsen E" first="E H" last="Jakobsen">E H Jakobsen</name><affiliation><nlm:affiliation>Department of Oncology, Vejle Hospital/Lillebaelt Hospital, Vejle, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Kaklamani, V" sort="Kaklamani, V" uniqKey="Kaklamani V" first="V" last="Kaklamani">V. Kaklamani</name><affiliation><nlm:affiliation>Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Gradishar, W" sort="Gradishar, W" uniqKey="Gradishar W" first="W" last="Gradishar">W. Gradishar</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Ratajczak, C K" sort="Ratajczak, C K" uniqKey="Ratajczak C" first="C K" last="Ratajczak">C K Ratajczak</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Nickner, C" sort="Nickner, C" uniqKey="Nickner C" first="C" last="Nickner">C. Nickner</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Qin, Q" sort="Qin, Q" uniqKey="Qin Q" first="Q" last="Qin">Q. Qin</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Qian, J" sort="Qian, J" uniqKey="Qian J" first="J" last="Qian">J. Qian</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Shepherd, S P" sort="Shepherd, S P" uniqKey="Shepherd S" first="S P" last="Shepherd">S P Shepherd</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Isakoff, S J" sort="Isakoff, S J" uniqKey="Isakoff S" first="S J" last="Isakoff">S J Isakoff</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Puhalla, S" sort="Puhalla, S" uniqKey="Puhalla S" first="S" last="Puhalla">S. Puhalla</name><affiliation><nlm:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29045554</idno><idno type="pmid">29045554</idno><idno type="doi">10.1093/annonc/mdx505</idno><idno type="wicri:Area/PubMed/Corpus">000451</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000451</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.</title><author><name sortKey="Han, H S" sort="Han, H S" uniqKey="Han H" first="H S" last="Han">H S Han</name><affiliation><nlm:affiliation>Moffitt Cancer Center, Tampa, FL.</nlm:affiliation></affiliation></author><author><name sortKey="Dieras, V" sort="Dieras, V" uniqKey="Dieras V" first="V" last="Diéras">V. Diéras</name><affiliation><nlm:affiliation>Institut Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Robson, M" sort="Robson, M" uniqKey="Robson M" first="M" last="Robson">M. Robson</name><affiliation><nlm:affiliation>Weill Cornell Medical College, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Palacova, M" sort="Palacova, M" uniqKey="Palacova M" first="M" last="Palácová">M. Palácová</name><affiliation><nlm:affiliation>Masarykuv onkologický ústav, Brno, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Marcom, P K" sort="Marcom, P K" uniqKey="Marcom P" first="P K" last="Marcom">P K Marcom</name><affiliation><nlm:affiliation>Duke University; Durham, NC.</nlm:affiliation></affiliation></author><author><name sortKey="Jager, A" sort="Jager, A" uniqKey="Jager A" first="A" last="Jager">A. Jager</name><affiliation><nlm:affiliation>Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Bondarenko, I" sort="Bondarenko, I" uniqKey="Bondarenko I" first="I" last="Bondarenko">I. Bondarenko</name><affiliation><nlm:affiliation>Dnepropetrovsk Medical Academy, City Hospital #4, Dnipro, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Citrin, D" sort="Citrin, D" uniqKey="Citrin D" first="D" last="Citrin">D. Citrin</name><affiliation><nlm:affiliation>Midwestern Regional Medical Center, Zion, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Campone, M" sort="Campone, M" uniqKey="Campone M" first="M" last="Campone">M. Campone</name><affiliation><nlm:affiliation>Institut de Cancérologie de l'Ouest, Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="Telli, M L" sort="Telli, M L" uniqKey="Telli M" first="M L" last="Telli">M L Telli</name><affiliation><nlm:affiliation>Stanford University School of Medicine, Stanford, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Domchek, S M" sort="Domchek, S M" uniqKey="Domchek S" first="S M" last="Domchek">S M Domchek</name><affiliation><nlm:affiliation>University of Pennsylvania, Philadelphia, PA.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M" last="Friedlander">M. Friedlander</name><affiliation><nlm:affiliation>Prince of Wales Hospital, Sydney, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kaufman, B" sort="Kaufman, B" uniqKey="Kaufman B" first="B" last="Kaufman">B. Kaufman</name><affiliation><nlm:affiliation>Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Garber, J E" sort="Garber, J E" uniqKey="Garber J" first="J E" last="Garber">J E Garber</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Shparyk, Y" sort="Shparyk, Y" uniqKey="Shparyk Y" first="Y" last="Shparyk">Y. Shparyk</name><affiliation><nlm:affiliation>Chemotherapy Department, Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine.</nlm:affiliation></affiliation></author><author><name sortKey="Chmielowska, E" sort="Chmielowska, E" uniqKey="Chmielowska E" first="E" last="Chmielowska">E. Chmielowska</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Oncology Centre, Bydgoszcz, UMK, Torun, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Jakobsen, E H" sort="Jakobsen, E H" uniqKey="Jakobsen E" first="E H" last="Jakobsen">E H Jakobsen</name><affiliation><nlm:affiliation>Department of Oncology, Vejle Hospital/Lillebaelt Hospital, Vejle, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Kaklamani, V" sort="Kaklamani, V" uniqKey="Kaklamani V" first="V" last="Kaklamani">V. Kaklamani</name><affiliation><nlm:affiliation>Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Gradishar, W" sort="Gradishar, W" uniqKey="Gradishar W" first="W" last="Gradishar">W. Gradishar</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Ratajczak, C K" sort="Ratajczak, C K" uniqKey="Ratajczak C" first="C K" last="Ratajczak">C K Ratajczak</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Nickner, C" sort="Nickner, C" uniqKey="Nickner C" first="C" last="Nickner">C. Nickner</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Qin, Q" sort="Qin, Q" uniqKey="Qin Q" first="Q" last="Qin">Q. Qin</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Qian, J" sort="Qian, J" uniqKey="Qian J" first="J" last="Qian">J. Qian</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Shepherd, S P" sort="Shepherd, S P" uniqKey="Shepherd S" first="S P" last="Shepherd">S P Shepherd</name><affiliation><nlm:affiliation>AbbVie Inc., North Chicago, IL.</nlm:affiliation></affiliation></author><author><name sortKey="Isakoff, S J" sort="Isakoff, S J" uniqKey="Isakoff S" first="S J" last="Isakoff">S J Isakoff</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Puhalla, S" sort="Puhalla, S" uniqKey="Puhalla S" first="S" last="Puhalla">S. Puhalla</name><affiliation><nlm:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29045554</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>18</Day></DateCreated><DateRevised><Year>2017</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdx505</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.</AbstractText><AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Eligible patients ≥18 years with locally recurrent or metastatic breast cancer and a deleterious BRCA1/2 germline mutation were randomized 1:1:1 to VCP, VT, or placebo plus carboplatin/paclitaxel (PCP). Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and overall response rate (ORR).</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Of 290 randomized patients, 284 were BRCA+, confirmed by central laboratory. For VCP versus PCP, median PFS was 14.1 and 12.3 months, respectively (hazard ratio [HR], 0.789; 95% CI, 0.536-1.162; P=0.227), interim median OS 28.3 and 25.9 months (HR, 0.750; 95% CI, 0.503-1.117; P = 0.156), and ORR 77.8% and 61.3% (P = 0.027). For VT (versus PCP), median PFS was 7.4 months (HR, 1.858; 95% CI, 1.278-2.702; P=0.001), interim median OS 19.1 months (HR, 1.483; 95% CI, 1.032-2.131; P=0.032), and ORR 28.6% (P<0.001). Safety profile was comparable between carboplatin/paclitaxel arms. Adverse events (all grades) of neutropenia, anemia, alopecia, and neuropathy were less frequent with VT versus PCP.</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Numerical but not statistically significant increases in both PFS and OS were observed in patients with BRCA1/2-mutated recurrent/metastatic breast cancer receiving VCP compared to PCP. The addition of veliparib to carboplatin/paclitaxel significantly improved ORR. There was no clinically meaningful increase in toxicity with VCP versus PCP. VT was inferior to PCP. An ongoing phase III trial is evaluating VCP versus PCP, with optional continuation single-agent therapy with veliparib/placebo if chemotherapy is discontinued without progression, in this patient population. Clinical trial information: NCT01506609.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diéras</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institut Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palácová</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Masarykuv onkologický ústav, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcom</LastName><ForeName>P K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Duke University; Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jager</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondarenko</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dnepropetrovsk Medical Academy, City Hospital #4, Dnipro, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citrin</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Midwestern Regional Medical Center, Zion, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campone</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Cancérologie de l'Ouest, Saint Herblain, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telli</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domchek</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Prince of Wales Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garber</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shparyk</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chemotherapy Department, Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chmielowska</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Oncology Centre, Bydgoszcz, UMK, Torun, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakobsen</LastName><ForeName>E H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Oncology, Vejle Hospital/Lillebaelt Hospital, Vejle, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaklamani</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradishar</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratajczak</LastName><ForeName>C K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickner</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Q</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>S P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isakoff</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puhalla</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PARP inhibitors</Keyword><Keyword MajorTopicYN="N">metastatic breast cancer</Keyword><Keyword MajorTopicYN="N">platinum</Keyword><Keyword MajorTopicYN="N">temozolomide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29045554</ArticleId><ArticleId IdType="pii">4282670</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdx505</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000451 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000451 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29045554
|texte= Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29045554" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |